InvestorsHub Logo

ignatiusrielly35

12/20/23 10:58 AM

#443373 RE: Anshu2 #443372

Yet the EMA saw the full data and approved filing for unconditional approval. Duh.

boi568

12/20/23 11:01 AM

#443374 RE: Anshu2 #443372

What we have 1.5 years after the AD trial is a green light by the EMA to submit an unconditional, EU-wide MAA application (equivalent to an NDA, except with even better odds for approval), opening the door to a multi-billion dollar market for blarcamesine in 2025.

The fact is that they have seen the full data. The fact that you haven't seen the full data is meaningless.

bas2020

12/20/23 11:04 AM

#443375 RE: Anshu2 #443372

Adam, is that you? LOL

nor377

12/20/23 11:32 AM

#443377 RE: Anshu2 #443372

Well, we, the blinded ones, are now obviously not the only ones that see the data as good. But say what you will, it’s the results that really matter.

Graniteguy

12/20/23 11:35 AM

#443378 RE: Anshu2 #443372

Who should we believe? Anshu2 is not a credible source of reliable and unbiased information. You certainly don’t pass the smell test and reek of special interests. I’ll safely side with the European Medical Association versus your negative opinion on all things Anavex Life Science.